LCM
ECYT

Leisure Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Leisure Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-27,391
Closed -$486K – 138
2018
Q3 		$486K Sell
27,391
-2,969
-10% -$51K 0.39% 97
2018
Q2 		$419K Buy
30,360
+2,582
+9% +$30.6K 0.36% 101
2018
Q1 		$253K Sell
27,778
-526
-2% -$2.9K 0.22% 119
2017
Q4 		$121K Buy
28,304
+581
+2% +$2.77K 0.1% 111
2017
Q3 		$39K Sell
27,723
-523
-2% -$729 0.03% 107
2017
Q2 		$42K Sell
28,246
-953
-3% -$2.05K 0.04% 111
2017
Q1 		$75K Sell
29,199
-839
-3% -$1.94K 0.07% 103
2016
Q4 		$77K Buy
30,038
+563
+2% +$1.62K 0.07% 104
2016
Q3 		$91K Sell
29,475
-199
-0.7% -$620 0.09% 98
2016
Q2 		$95K Buy
29,674
+19
+0.1% +$70 0.09% 100
2016
Q1 		$92K Hold
29,655
– – 0.09% 98
2015
Q4 		$119K Buy
29,655
+724
+3% +$3.33K 0.11% 103
2015
Q3 		$133K Buy
28,931
+918
+3% +$4.8K 0.14% 86
2015
Q2 		$145K Buy
28,013
+1,648
+6% +$9.88K 0.14% 88
2015
Q1 		$165K Buy
26,365
+1,732
+7% +$10K 0.16% 84
2014
Q4 		$155K Buy
+24,633
New +$150K 0.15% 85

Other funds holding ECYT

OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
CA
Claro Advisors Boston, Massachusetts $830M AUM 21.8% 1-Year Est. Return

Leisure Capital Management's ECYT Position: Q4 2018 in Review

Leisure Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 27,391 shares — an estimated $486K sold.

Leisure Capital Management first reported a position in ECYT in Q4 2014 and held it in 16 quarters. The position peaked at $486K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

  • Leisure Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Leisure Capital Management sold 27,391 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $486K.
  • Leisure Capital Management first reported a position in Endocyte, Inc. Common Stock in Q4 2014 and held it in 16 quarters.
  • Leisure Capital Management's Endocyte, Inc. Common Stock position peaked at $486K in Q3 2018.
  • 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Leisure Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.